TuHURA Biosciences

TuHURA presented an immuno‑oncology strategy with three platforms at the Canaccord Growth Conference and is moving the lead IFx program into a randomized phase‑III trial (118 patients) in combination with pembrolizumab; an FDA Special Protocol Assessment could enable accelerated approval. The company received a non‑dilutive loan facility of $50m from its largest shareholder to fund development. Separately, the VISTA inhibitor TBS‑2025 is approaching first‑in‑human use in NPM1‑mutated AML, and an ADC platform has produced early preclinical data. TuHURA expects to complete phase‑III recruitment in H2 2027 and report top‑line data in late 2027/early 2028. » Más en de.investing.com

TuHURA enters into a credit facility of up to $50 million with a subsidiary of K&V Investment One (largest shareholder); borrowed amounts carry a 12% annual interest rate, interest payable monthly, principal due April 21, 2031, and the facility is secured by company and subsidiary assets. The funds are intended to finance clinical development and operations as needed; TuHURA also grants the lender a low- to mid-single-digit percentage royalty on revenues from IFx-2.0 products. The financing comes amid acute liquidity pressure (current ratio 0.78, levered FCF -$27.71 million) and is intended to support the company until key Phase 3 milestones for IFx-2.0. » Más en de.investing.com

TuHURA Biosciences has appointed Amanda Garofalo as Senior Vice President of Clinical Operations; she brings more than 20 years of clinical trial development experience and will oversee day‑to‑day clinical operations. The company is running a phase‑3 study of IFx‑2.0 as an adjuvant therapy to Keytruda in Merkel cell carcinoma and is also developing TBS‑2025 (a VISTA‑inhibiting mAb) as well as antibody‑drug conjugates targeting myeloid suppressor cells. Garofalo joins from Parabilis Medicines and has held senior roles at several biotech firms. TuHURA, however, faces financial headwinds: market capitalization of USD 87.4 million, current ratio 0.78, significant cash‑burn concerns and a share price decline of nearly 19% in the past week. » Más en de.investing.com